
Bio-Techne Operating Income Surges 95% Despite 2% Revenue Dip
Bio-Techne CorporationDescription
What this story covers
Bio-Techne demonstrated strong fiscal discipline in Q3 2026, nearly doubling operating income to $75.5 million through aggressive cost-cutting. Despite a 2% revenue decline and divestiture impacts, the company significantly reduced debt to prepare for a $1 billion acquisition commitment.
Story snapshot
CompanyBio-Techne Corporation
TickerTECH
VariantStandard detailed
Duration13:45
Filing type10-Q
PeriodQ4 2026
IndustryHealthcare & Pharmaceuticals
Accession0001104659-26-056302
Sources1
Full Story Script
Content not available for this story.